Highlight Therapeutics
2 known investors
Highlight Therapeutics develops RNA-based immunotherapies for dermato-oncology, with a lead intra-lesional drug candidate, BO-112, aimed at triggering an immune response against skin cancers. Its clinical program targets patients with skin cancers such as basal cell carcinoma.
BiotechHealthtech
Investors · 2
Frequently asked questions
- What does Highlight Therapeutics do?
- Highlight Therapeutics develops RNA-based immunotherapies for dermato-oncology, with a lead intra-lesional drug candidate, BO-112, aimed at triggering an immune response against skin cancers. Its clinical program targets patients with skin cancers such as basal cell carcinoma.
- Who are Highlight Therapeutics's investors?
- Highlight Therapeutics's investors include Droia Ventures, Columbus Venture Partners.